ovestin tafla 1 mg
aspen pharma trading limited - estriolum inn - tafla - 1 mg
ovestin tafla 2 mg
aspen pharma trading limited - estriolum inn - tafla - 2 mg
vivelle dot forðaplástur 100 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 100 míkróg
vivelle dot forðaplástur 25 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 25 míkróg
vivelle dot forðaplástur 37,5 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg
vivelle dot forðaplástur 50 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg
vivelle dot forðaplástur 75 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg
intrarosa
endoceutics s.a. - prasterone - postmenopause - Önnur hormón kynlíf og stillum kynfæri - intrarosa er ætlað til meðferðar á kuldahrollfrumum og kviðverkjum hjá konum eftir tíðahvörf með miðlungsmikil til alvarleg einkenni.
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - sykursýki, tegund 2 - lyf notuð við sykursýki - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
livial tafla 2,5 mg
n.v. organon* - tibolonum inn - tafla - 2,5 mg